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Background: Vulnerability to stress has been associated to distress, emotional distress symptoms and metabolic
control in type 2 diabetes mellitus (T2DM) patients as well. Furthermore some conflicting results were noticed. We
aimed to evaluate the effect over metabolic control in what concerns vulnerability to stress beyond depressive and
anxiety symptoms.
Findings: This cross-sectional study assessed 273 T2DM patients with depressive and anxiety symptoms using the
Hospital Anxiety Depression Scale (HADS) and the 23 Questions to assess Vulnerability to Stress (23QVS), along with
demographic and clinical diabetes-related variables. Hierarchical logistic regression models were used to investigate
predictors of poor glycemic control. The results showed an association of depressive symptoms (odds ratio = 1.12,
95%CI = 1.01-1.24, P = 0.030) with increased risk of poor glycemic control. Anxiety symptoms and vulnerability to
stress on their own were not predictive of metabolic control, respectively (odds ratio = 0.92, 95%CI = 0.84-1.00,
P = 0.187 and odds ratio = 0.98, 95%CI = 0.95-1.01, P = 0.282).
Conclusions: Our data suggested that vulnerability to stress was not predictive of poor glycemic control in T2DM,
but depressive symptoms were.
Keywords: Type 2 diabetes mellitus, Vulnerability to stress, Metabolic control, Depressive symptoms, Anxiety
symptomsFindings
Background
Concept of stress concerns to an acute or chronic stress-
ful event itself or either the biological or psychological
response to such conditions [1]. In a major chronic dis-
ease such as type 2 Diabetes Mellitus (T2DM), stress
comes potentially from two cumulative sources, namely,
specific diabetes-related psychological distress, asso-
ciated with repetitive intrusive treatment regimens or
disabling chronic complications, and the generic daily
life psychological stress of living with a chronic disease
in a complex world with professional and interpersonal
challenges [2].
Vulnerability to stress represents a general tendency to
experience intense episodes of distress and negative* Correspondence: carlosgois13@gmail.com
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reproduction in any medium, provided the oraffects and it is also a risk factor for depression or anx-
iety disorders [3-5]. Patients with T2DM with more vul-
nerability to stress, such as anxiety, neuroticism,
timidity, less resilience, less social support and lower
standards of living have been associated to contradictory
results concerning the glycemic control [6-14]. Anxiety
and depression have also been related to metabolic con-
trol [15-18] although some recent studies have yielded
conflicting results [19-21]. Depressive symptoms and
diabetes-specific distress are correlated to each other, al-
though only specific distress displayed more linkages
with behavioral and glycemic control [21-27]. In this
sense, it seems that affective symptoms covariate with
the negative emotional component of diabetes-specific
distress, although one cannot always notice disturbances
in what concerns metabolic control [19].
The aim of this study was to evaluate whether vulner-
ability to stress has any additional value beyond depres-
sive or anxiety symptoms on glycemic control.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Sample
This study was included in a screening protocol to de-
tect depressive and anxiety states in patients with T2DM
who have been followed up at the Portuguese Diabetes
Association (APDP).
Diagnostics for patients with T2DM had to be estab-
lished for at least 6 months earlier and followed up at
the APDP for at least another 3 months. Patients’ age
ranged from 18 to 65, and all had to be able to fill in the
questionnaires and previously tested for HbA1c control.
Patients with history of cerebrovascular disease were
excluded. While waiting for their regular diabetes con-
sultation 317 consecutive patients with T2DM were
invited to participate in this study after detailed
explanation.
The study was approved by local Ethics Committee of
the APDP and all participants provided prior written
informed consent in accordance with the ethical stan-
dards of the Helsinki Declaration.
Measures
A clinical interview was carried out with all patients,
and information was collected concerning demographic
and clinical data, namely body mass index (BMI), HbA1c
level, diabetes therapy and antidepressant medication.
All patients filled in clinical questionnaires. Chronic
complications due to diabetes were identified by taking
each patient’s medical history, symptoms, physical-
evaluation findings and automated data into account.
Medical records were used to check and complete data.
The hospital anxiety depression scale (HADS) This
self-report scale was designed to detect depressive and
anxiety symptoms, and has 14 questions, seven on anx-
iety and seven on depression having only an answer to
each question along a 0 to 3 points scale [28]. Final
score ranges from 0 to 21 points for each sub-scale and
a higher score means the presence of increased anxious
or depression symptoms. A score ranging 0 to 7 is “nor-
mal”; from 8 to 10, “light”; from 11 to 14 “moderate”
and from 15 to 21 “serious”. The version used was a Por-
tuguese edition with Cronbach’s alpha = 0.81 for the de-
pression sub-scale and 0.76 for anxiety. A sub-group of
316 patients with T2DM was included in the validation
sample [29]. HADS continuous scores were used in our
analysis.
The 23 questions to assess vulnerability to stress
(23QVS) This self-rating scale assesses the vulnerability
to generic stress [30]. Through a literature review, 64
questions related to stress vulnerability facets were
obtained. These facets were: negative and positive per-
sonality characteristics, regular exercise, confidentavailability, social and family support and adverse life
conditions. Items were suppressed to obtain the final
version based on: (a) absence of significant positive cor-
relation with the neuroticism factor in Portuguese ver-
sion of the Eysenck Personality Inventory (Eysenck,
1964) and psychopathology index at the Portuguese ver-
sion of Brief Symptom Inventory (Derogatis, 1982) and
absence of significant negative correlation with positive
coping score from Problems Resolution Inventory, a
Portuguese coping questionnaire (Vaz Serra, 1988) [31];
(b) significant differences by gender; (c) homogeneity
problems, detected by Cronbach α changes after remov-
ing an item; (d) ceiling effects of some questions. Final
version comprises 23 questions requiring only an answer
for each question out of a range of 0 to 4; some items
earns direct scores, while others scored reversely. High-
est score always indicates greatest vulnerability to stress.
Reliability and validity were performed on a sample of
368 subjects from general population. Cronbach’s alpha
coefficient was 0.82 and test-retest r = 0.816, P< 0.001.
Using factor analysis, seven main factors came out
explaining 57.5% variance: Factor 1 – Perfectionism and
intolerance to frustration, e.g. “I feel bad when I don’t
excel in what I do”; Factor 2 – Inhibition and functional
dependence, e.g. “I’m more likely to complain about rou-
tine set-backs than make an effort to solve them”; Factor
3 – Lack of social support, e.g. “When I’ve got a problem
I’ve usually got someone to help me”(reverse score); Fac-
tor 4 – Adverse living conditions, e.g. “I have enough
money to take care of my personal needs”(reverse score);
Factor 5 – Dramatization of existence, e.g. “I’m the sort
of easy-going person who makes a joke out of my mis-
haps”(reverse score); Factor 6 – Subjugation, e.g. “I
spend more time helping others than I spend on my
own needs”; Factor 7 – Deprivation of affection and re-
jection, e.g. “I’ve got unpleasant traits that put others
off”. The 23QVS includes both individual and social vul-
nerability factors, which is considered to be a faster,
more practical way of detecting vulnerability to stress in-
stead of applying several scales to each factor. The scale
comprising scores was fed into a computerized program
devised by the test’s author. The 23QVS continuous
score was used in our analysis.
The HbA1c values were determined at APDP using
ion-exchange high-performance liquid chromatography,
in a BIO-RAD Variant II turbo kit (according to the
manufacturing data range 4.9–6.2%). HbA1c values were
divided into 2 groups (<8% and ≥8%) to describe gly-
cemic control for each subject, in accordance to previ-
ous reports [24,32,33].
Statistical analysis
All variables were described by undertaking the whole
sample and the comparison between subgroups of
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and chi-square test were used to compare demographic,
clinical and psychometric variables to all the patients in
univariate analyses when the sample was divided to
dichotomized HbA1c.
To evaluate the risk of poor glycemic control asso-
ciated to vulnerability to stress beyond depressive or
anxiety symptoms, a logistic hierarchical regression ana-
lysis was used. Analyses were performed with HbA1c
dichotomized as dependent variable (≥8%=1) and vari-
ables were entered in several blocks according to demo-
graphic variables, clinical variables, depressive and
anxiety symptoms and vulnerability to stress. To check
for multicollinearity we performed Pearson correlations
on independent variables prior to logistic regressions
analyses.
Odds ratio were used instead of size effects because
we were dealing with logistic regression analysis [34]. A
P value <0.05 was used to determine the level of statis-
tical relevance. Statistical analysis was carried out using
the SPSS 15.0 (SPSS Inc., Chicago, Illinois).Results and discussion
Patients’ characteristics
The study sample comprised a group of two-hundred
and seventy three T2DM patients (139 men and 134
women). A total of 317 patients were invited and 28
were not eligible: short follow up at APDP (n = 9), recent
T2DM diagnosis (n = 2), unable to fill in questionnaires
(n = 4), previous stroke (n = 1), missing HbA1c level
(n = 12). From eligible patients, 7 refused to participate
(response rate = 97.5%). Their demographic features (age,
gender and education) were not different from those
included in the study. Due to missing data, 9 patients
were further eliminated from analysis.
Participant patients with worse metabolic control were
younger (mean = 59.15, SD= 4.69 vs. mean = 56.74, SD=
6.26, t = 3.63, P< 0.001), insulin users (43.0% vs. 68.1%,
X2 = 16.82, P< 0.001) with higher score on HADS de-
pression (mean = 3.93, SD= 3.11 vs. mean = 4.7, SD=
3.84, t =−2.00, P = 0.047). (Table 1)Predictors of poor glycemic control
After ensuring for lack of multicollinearity among vari-
ables by checking bivariate correlations (all ≤ r = 0.543,
Pearson’s correlation coefficient between HADS anxiety
and 23QVS), hierarchical logistic regressions were con-
ducted (Table 2). Both significant demographic and clin-
ical predictors for worse metabolic control (HbA1c ≥ 8)
were younger and insulin users. HADS depression was
associated with an increase risk of poor metabolic con-
trol in all models. Both HADS anxiety and 23QVS were
not predictive of worse metabolic control.Discussion and conclusion
The aim of our cross-sectional study was to evaluate
whether vulnerability to generic stress is predictive of
poor metabolic control in patients with T2DM beyond
depression or anxiety. Analysis was done adjusting for
several demographic and clinical features, such as
chronic complications, insulin use and antidepressants.
In our study, vulnerability to stress was not predictive of
poor metabolic control. A significant association with
increased risk of worse metabolic control was shown
among patients with depressive symptoms. Anxiety
symptoms did not achieve a predictive value for worse
glycemic control.
Our findings are consistent with other studies report-
ing relations between depressive symptoms and poor
metabolic control in T2DM [15,16,18]. A literature
meta-analysis shows a small to moderate effect-size of
0.17 [95% CI 0.13-0.21] similar in studies of type 1 or
type 2 diabetes [15]. Depressive symptoms have an im-
pact on metabolic control by behavioral or biological in-
volvement. In a primary care sample of T2DM patients,
depressive symptoms were incrementally related to
poorer self-care behaviors, including lower adherence to
diet, exercise recommendation and prescribed medica-
tion [35]. A biological proposed mechanism underlying
depression and diabetes concerns pathophysiologic con-
ditions such as activation of hypothalamic pituitary adre-
nocortical axis and sympathomedullary axis with an
increased release of cortisol and catecholamines. More-
over, reduced activity associated to depression might
lead to development of obesity, cytokines release and in-
sulin resistance, even more deteriorating glycemic con-
trol [36]. Depression among T2DM patients has been
described as a long lasting condition, with 58% recur-
rences during the first year after index depressive epi-
sode. About 79% of patients who were already depressed
when recruitment took place reported at least one recur-
rence of depressive episode during the 5 years period the
study lasted [37].
Outside distress emotional situations, vulnerability to
stress may encompass two quiet different life paths.
Those who are pessimistic and anxious will fail to adhere
to treatment regimens, engage in unhealthy lifestyle, and
have disrupted homeostasis, lack of social support and
increased poor health and those who leads to neurotic
vigilance, treatment adherence and better health [38].
Patients with T2DM having no psychiatric conditions
and neuroticism personality traits, presented better
metabolic control. Probably, the sense of distress could
motivate to a better insight level regarding the need to
find effective coping strategies [13]. The hypothesis of
off-setting heterogeneous behaviors concerning diabetes
and its treatment among vulnerable to stress patients
may explain the lack of association with metabolic
Table 1 Sample description
Total sample Patients by glycemic control level
N= 273 N=107 N=166
HbA1c< 8 HbA1c≥ 8 P
Age (years) 57.68 ± 5.81 59.15 ± 4.69 56.74 ± 6.26 0.001
Gender (male) 139 (50.9) 54 (50.5) 85 (51.2) 1.000
Education level (years) 7 ± 4.20 7.23 ± 4.29 6.85 ± 4.14 0.469
BMI (kg/m2) 30.08 ± 4.42 30.02 ± 4.37 30.12 ± 4.50 0.858
Diabetes duration 13.95 ± 7.08 13.44 ± 7.91 14.27 ± 6.49 0.346
≥ 1 chronic complications 132 (48.4) 46 (43.0) 86 (51.8) 0.173
Insulin users 159 (58.2) 46 (43.0) 113 (68.1) <0.001
Antidepressant users 31 (11.4) 12 (11.2) 19 (11.4) 1.000
HbA1c 8.68 ± 1.71
HADS depression 4.45 ± 3.59 3.93 ± 3.11 4.7 ± 3.84 0.047
HADS anxiety 7.24 ± 3.84 7.31 ± 3.94 7.19 ± 3.78 0.803
23QVS 42.70 ± 10.59 42.61 ± 9.20 42.76 ± 11.43 0.910
Data are means ± SD or n (%). P values based on Student’s test or X² test comparing between those with HbA1c< 8 or ≥8.
Legend: HADS: The Hospital Anxiety and Depression Scale; 23QVS: The 23 Questions to assess Vulnerability to Stress, BMI: Body Mass Index; HbA1c: Hemoglobin
A1c.
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alone, usually more associated to less emotionally stable
subjects, is associated to negative health outcomes.
However, when emotion-focused coping precedes and
fosters problem-focused coping which begins afterwards,
it leads to increased medical adherence [39]. Otherwise
in a study designed to predict which T2DM patients
would have better response to addition of relaxationTable 2 Multivariate hierarchical logistic regression with meta
Model 1 M
Age (years) 0.92 (0.87-0.96)** 0.91 (0
Gender 0.98 (0.59-1.63) 1.04 (
Education level (years) 0.96 (0.91-1.02) 0.96 (
BMI (kg/m2) 1.01 (
Diabetes duration 1.02 (
≥ 1 chronic complications 1.13 (
Insulin users 2.69 (1




Nagelkerke R2 0.065 0
Cox&Snell R2 0.048 0
Model X2 13.4** 3
1st block: Demographic variables: age, gender (male = 1), education; 2nd block: Demo
complications (yes = 1), insulin users (yes = 1), antidepressants users (yes = 1); 3rd blo
depression; 4th block: Demographic, Clinical, Psychometric variables HADS anxiety,
Legend: HADS: The Hospital Anxiety and Depression Scale; 23QVS: The 23 Question
A1c. Significance level: *P< 0.05;**P< 0.01;***P< 0.001.training in their standard intensive therapy, none of the
individual differences related to stress reactivity
explained the variability in the changes in HbA1c [8]. In
another study, a significant reduction of 0.5% in HbA1c
was achieved after 12-month follow-up in the group re-
ceiving stress management treatment against the group
receiving diabetes education alone, but stress-
responsiveness individual features were not associatedbolic control (HbA1c <8 and ≥8) as dependent variable
odel 2 Model 3 Model 4
.86-0.96)** 0.90 (0.85-0.95)*** 0.90 (0.85-0.95)***
0.61-1.78) 1.06 (0.60-1.88) 1.06 (0.60-1.88)
0.91-1.02) 0.97 (0.91-1.03) 0.96 (0.89-1.02)
0.95-1.07) 1.01 (0.95-1.07) 1.01 (0.95-1.07)
0.98-1.06) 1.02 (0.98-1.06) 1.02 (0.98-1.06)
0.66-1.94) 1.09 (0.63-1.90) 1.11 (0.64-1.93)
.57-4.59)*** 2.64 (1.53-4.54)*** 2.65 (1.54-1.58)***
0.50-2.62) 1.06 (0.45-2.48) 1.09 (0.46-2.57)
1.13 (1.02-1.24)* 1.14 (1.03-1.27)**





graphic and Clinical variables: BMI, diabetes duration, ≥ 1 chronic
ck: Demographic, Clinical and Psychometric variables HADS anxiety, HADS
HADS depression and 23QVS. Results: OR (95% CI).
s to assess Vulnerability to Stress, BMI: Body Mass Index; HbA1c: Hemoglobin
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factor between vulnerability to stress and glycemic con-
trol was not evaluated or reflects a dynamic changing
interaction with contingent strategies between an indi-
vidual and the circumstances [40]. Type 2 Diabetes as an
“if-then” disease in daily life adaptation may fit well with
this last statement that may be rather difficult to capture
in research. We argue that when people with vulnerabil-
ity to stress get depressed, adaptation to generic or spe-
cific stressors becomes more ineffective and enduring
with negative consequences to glycemic outcome by be-
havioral or biologic pathways.
No association of anxiety symptoms to worse meta-
bolic control was found. Anxiety has been associated to
metabolic control, although with conflicting results. In a
prospective study with T2DM patients, anxiety seemed
to facilitate earlier detection of diabetes, however
6 months afterwards impact of diagnosis was stronger in
anxious individuals [41]. In a meta-analysis with type 1
or 2 diabetes patients, only anxiety disorders were asso-
ciated to hyperglycemia, but not sub-clinical anxiety
symptoms [17]. Nevertheless, in recent studies, T2DM
patients did not present an association regarding their
anxiety disorder or symptoms with HbA1c [18,21].
In clinical practice, our results come up with the rele-
vance of assessing depression in T2DM patients to bet-
ter approach glycemic control deterioration. Patients
with vulnerability to stress were not associated with
increased risk of worse metabolic control, but they rep-
resent a population with a greater tendency to become
depressed. A closer monitoring with regular depression
assessment is advisable with such vulnerable patients.
Several limitations should be addressed to our study.
The cross-sectional nature of the study prohibits any
statements with respect to causality. Being in poor gly-
cemic control over longer periods of time may also
cause serious distress and depression [27,33]. Prospect-
ive studies are desirable to clarify the particular role and
implication of vulnerability to generic stress to metabolic
control in symptomatic or asymptomatic patients and
clarify what are the possible mediators involved. We
used continuous scores concerning depression, but a
diagnostic psychiatric interview remains the gold stand-
ard in research and clinical practice.
The most robust finding of our study was that depres-
sive symptoms are associated with glycemic control but
vulnerability to stress is not.
Further studies are needed to better clarify the rela-
tionship between anxiety symptoms and metabolic con-
trol in these patients.Abbreviations
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